UPDATING the CLINICAL-EXPERIENCE in ENDOMETRIOSIS - the BRAZILIAN PERSPECTIVE

UPDATING the CLINICAL-EXPERIENCE in ENDOMETRIOSIS - the BRAZILIAN PERSPECTIVE

Autor Halbe, H. W. Google Scholar
Nakamura, M. S. Google Scholar
Dasilveira, GPG Google Scholar
Carvalho, WPC Google Scholar
Instituição Universidade de São Paulo (USP)
FED SCH MED SCI
Universidade Federal de São Paulo (UNIFESP)
Resumo In an open-label, multicentre, randomized, parallel group study, 164 women with endometriosis were assigned to treatment. Out of these women, 81 received danazol (600 mg daily for 8 weeks, then 400 mg for 16 weeks) and 83 were given gestrinone (2.5 mg twice a week for 24 weeks). Five weeks before the start of treatment clinical evaluation and diagnostic laparoscopy were performed during the screening visit. Drug assignment and laboratory data assessment were carried out within 3 days of the estimated onset of the menstrual cycle at baseline visit. the response to treatment was assessed during visits at weeks 2, 4, 8, 12, 16, 20 and 24; at the last visit a second laparoscopy was performed. Therapeutic efficacy was evaluated by analysis of the laparoscopic scores assessed according to the revised American Fertility Society classification. Symptomatic response was measured by clinical scores and laboratory data. in one centre, bone mineral density was also recorded. One patient in the danazol group discontinued treatment due to a cutaneous rash as a probable adverse reaction at the beginning of the study. the therapeutic efficacy of danazol and gestrinone did not differ significantly when the revised American Fertility Society scores were compared. the symptomatic response also showed no statistical difference when clinical examination scores were analysed. There was no significant difference between the drugs in laboratory data, including bone mineral density, with respect to adverse events. Analysis of clinical scores showed that danazol was superior to gestrinone with respect to acne and irregular bleeding. Based on these data, we conclude that both danazol and gestrinone are reliable in the treatment of endometriosis and offer similar results.
Idioma Inglês
Data de publicação 1995-10-01
Publicado em British Journal of Obstetrics and Gynaecology. Oxford: Blackwell Science Ltd, v. 102, p. 17-21, 1995.
ISSN 0306-5456 (Sherpa/Romeo, fator de impacto)
Publicador Blackwell Science Ltd
Extensão 17-21
Fonte http://dx.doi.org/10.1111/j.1471-0528.1995.tb09161.x
Direito de acesso Acesso restrito
Tipo Artigo
Web of Science WOS:A1995RZ53700006
Endereço permanente http://repositorio.unifesp.br/handle/11600/25531

Exibir registro completo




Arquivo

Arquivo Tamanho Formato Visualização

Não existem arquivos associados a este item.

Este item está nas seguintes coleções

Buscar


Navegar

Minha conta